Search
PolyPid Ltd
PYPDAdd to Watchlist
4.460USD
+0.080+1.83%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
85.52MMarket Cap
LossP/E TTM
More Details of PolyPid Ltd Company
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
PolyPid Ltd Info
Ticker SymbolPYPD
Company namePolyPid Ltd
IPO dateJun 26, 2020
CEOAkselbrad (Dikla Czaczkes)
Number of employees57
Security typeOrdinary Share
Fiscal year-endJun 26
Address18 Hasivim Street, P.O Box 7126
CityPETAH TIKVA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code4917002
Phone972747195700
Websitehttps://www.polypid.com
Ticker SymbolPYPD
IPO dateJun 26, 2020
CEOAkselbrad (Dikla Czaczkes)
Company Executives of PolyPid Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
--
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mrs. Anat Tsour Segal
Mrs. Anat Tsour Segal
Independent Director
Independent Director
--
--
Dr. Shaul Mukhtar, Ph.D.
Dr. Shaul Mukhtar, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Ms. Dalit Hazan
Ms. Dalit Hazan
Senior Vice President - Research and Development and Regulatory Affairs
Senior Vice President - Research and Development and Regulatory Affairs
--
--
Mr. Nir Dror
Mr. Nir Dror
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Yechezkel Barenholz, Ph.D.
Dr. Yechezkel Barenholz, Ph.D.
Independent Director
Independent Director
2.76K
--
Ms. Dikla Czaczkes Akselbrad
Ms. Dikla Czaczkes Akselbrad
Chief Executive Officer, Director
Chief Executive Officer, Director
934.00
--
Dr. Itzhak Krinsky, Ph.D.
Dr. Itzhak Krinsky, Ph.D.
Independent Director
Independent Director
833.00
--
Mr. Jacob Harel
Mr. Jacob Harel
Independent Chairman of the Board
Independent Chairman of the Board
467.00
--
Mr. Ori Warshavsky
Mr. Ori Warshavsky
Chief Operating Officer - US
Chief Operating Officer - US
267.00
--
Dr. Noam Emanuel, Ph.D.
Dr. Noam Emanuel, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 7
Updated: Thu, May 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Aurum Ventures M.K.I.
18.60%
Hodges (Rodney)
10.71%
Centaurus Investments Limited
5.80%
AIGH Capital Management, LLC.
5.31%
Rosalind Advisors, Inc.
3.65%
Other
55.92%
Shareholders
Shareholders
Proportion
Aurum Ventures M.K.I.
18.60%
Hodges (Rodney)
10.71%
Centaurus Investments Limited
5.80%
AIGH Capital Management, LLC.
5.31%
Rosalind Advisors, Inc.
3.65%
Other
55.92%
Shareholder Types
Shareholders
Proportion
Venture Capital
18.77%
Individual Investor
15.53%
Hedge Fund
6.24%
Holding Company
5.80%
Private Equity
5.31%
Research Firm
1.22%
Investment Advisor
1.06%
Investment Advisor/Hedge Fund
1.00%
Other
45.06%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
33
6.41M
33.61%
+15.62K
2025Q4
32
6.78M
40.77%
+1.48M
2025Q3
28
6.76M
43.18%
+2.23M
2025Q2
41
7.60M
74.58%
+1.39M
2025Q1
42
7.66M
75.16%
+942.60K
2024Q4
44
5.48M
65.20%
+1.87M
2024Q3
50
4.47M
69.98%
+1.49M
2024Q2
58
3.43M
73.51%
+1.59M
2024Q1
59
3.33M
71.29%
+2.56M
2023Q4
54
443.78K
34.10%
+80.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Aurum Ventures M.K.I.
3.08M
16.15%
+1.06M
+52.19%
Jun 30, 2025
Hodges (Rodney)
2.04M
10.71%
+2.04M
--
Feb 19, 2026
Centaurus Investments Limited
1.11M
5.8%
+475.10K
+75.12%
Dec 31, 2024
AIGH Capital Management, LLC.
1.15M
6.03%
+379.82K
+49.23%
Dec 31, 2025
Rosalind Advisors, Inc.
696.56K
3.65%
-222.11K
-24.18%
Dec 31, 2025
Nir (Yehuda)
613.91K
3.22%
+62.60K
+11.36%
Mar 31, 2025
Lukach (Aharon)
299.55K
1.57%
-5.64K
-1.85%
Mar 31, 2025
Morgan Stanley & Co. LLC
208.12K
1.09%
+6.00K
+2.97%
Dec 31, 2025
Dafna Capital Management, LLC
207.90K
1.09%
--
--
Dec 31, 2025
Worth Venture Partners, LLC
191.56K
1%
-101.98K
-34.74%
Dec 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Date
Ex-dividend Date
Type
Ratio
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
Aug 30, 2023
Merger
30→1
